Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q9ZN
|
||||
| Former ID |
DNC007929
|
||||
| Drug Name |
3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H14Br2O3
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)COC2=C(C=C(C=C2Br)CCC(=O)O)Br
|
||||
| InChI |
1S/C16H14Br2O3/c17-13-8-12(6-7-15(19)20)9-14(18)16(13)21-10-11-4-2-1-3-5-11/h1-5,8-9H,6-7,10H2,(H,19,20)
|
||||
| InChIKey |
ZCVQDNGOBFARHQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Thyroid hormone receptor alpha | Target Info | Inhibitor | [1] | |
| Thyroid hormone receptor beta-1 | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Thyroid hormone signaling pathwayhsa04080:Neuroactive ligand-receptor interaction | |||||
| Thyroid hormone signaling pathway | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Nuclear Receptor transcription pathwayR-HSA-383280:Nuclear Receptor transcription pathway | ||||
| WikiPathways | Endochondral Ossification | ||||
| Nuclear ReceptorsWP706:SIDS Susceptibility Pathways | |||||
| Hematopoietic Stem Cell Differentiation | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2007 Apr 1;17(7):2018-21. Epub 2007 Jan 13.Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.